Severe renal toxicity following adjuvant envafolimab in a patient with ultra-hypermutated (POLE) stage II colorectal cancer: a case report
{{output}}
Background: POLE-mutated colorectal cancer (CRC) is a rare molecular subtype featured by ultra-high tumor mutational burden (TMB) and favorable prognosis, and adjuvant systemic therapy is generally not recommended for such patien... ...
